Gapping up
In reaction to earnings/guidance:
- XPER +25.6% (also announces license agreement with Comcast which ends all litigation between the cos), FLGT +15.5%, ZIXI +8.5% (also acquires privately-held CloudAlly), WES +7.8%, ZI +7.1%, CRSR +6.9%, IPAR +6.8%, BNTX +6.8%, SCOR +6.4%, TLND +5.1%, INO +4.1%, RNG +4.1% (also also announces expanded partnership with BT), TCP +3.8%, NCLH +3.4%, APPF +3.2%, BSY +3.1%, NGL +2.9%, ERJ +2.9%, HAIN +2.6%, DHT +1.7%, WPM +1.5% (also increases dividend), NKLA +1.4%, SWAV +1.2%, NOVT +1.2%, DIOD +1.1%
Other news:
- AFMD +12.6% (announces licensing and strategic collaboration agreement with Roivant Sciences)
- ALT +12.3% (partners with Lonza to supply of AdCOVID single-dose intranasal vaccine candidate for COVID-19)
- NK +8.6% (NantKwest and ImmunityBio announce positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study)
- VNOM +8.3% (announces $100 mln share buyback plan)
- CVAC +7.9% (publishes detailed interim phase 1 data of its COVID-19 vaccine candidate, CVnCoV)
- DBVT +7.8% (provides update on Viaskin Peanut Treatment Delivery at ACAAI 2020)
- AMGN +4.7% (reports NAVIGATOR Phase 3 Trial met primary endpoint)
- SFT +4.5% (launches car marketplace in Texas)
- PTON +4.4% (Peloton and Beyoncé announce a broad, multi-year partnership)
- DNLI +3.9% (announces first human biomarker proof of concept for its transport vehicle (TV) technology achieved in phase 1/2 study of ETV:IDS (DNL310) in hunter syndrome)
- BA +3.6% (awarded $660 mln Air Force contract)
- LLY +3.6% (Eli Lilly neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19)
- HDS +2.8% (Lowe's issues statement in response to media reports; not in discussions with HD Supply (HDS))
- LOW +1.6% (issues statement in response to media reports; not in discussions with HD Supply (HDS))
Analyst comments:
- MCS +8.3% (upgraded to Outperform from Mkt Perform at Barrington Research)
- SAN +8% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- SPR +5.9% (upgraded to Overweight from Neutral at JP Morgan)
- DDD +4.9% (upgraded to Mkt Perform from Underperform at William Blair)
- INO +4.6% (upgraded to Neutral from Sell at ROTH Capital)
- ICPT +3.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- LEVI +3.2% (upgraded to Buy from Neutral at BofA Securities)
- CHEF +2.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- RTX +2.4% (upgraded to Overweight from Neutral at JP Morgan)
- BIIB +1.6% (upgraded to Buy from Hold at DZ Bank)
- AINV +1.4% (upgraded to Overweight from Underweight at Wells Fargo)
- CB +1.4% (upgraded to Buy from Sell at Goldman)
- MAXN +1.2% (upgraded to Outperform from Mkt Perform at Raymond James)